Linomide inhibits insulitis and modulates cytokine production in pancreatic islets in the nonobese diabetic mouse

International Immunopharmacology

Volumn 3, Issue 1, 2003, Pages 17-30

  Dahlén, Eva ^a,c   Dawe, Kim ^a,d   Ohlsson, Lennart ^a   Hall, Håkan ^a,e   Hedse, Karin ^a   Annersten, Karin ^a   Åström, Mikael ^a   Gross, David J ^b   Hedlund, Gunnar ^a  

^a Active Biotech Research AB   (Sweden)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c Tumor Immunology   (Sweden)

^d Oxford GlycoSciences   (United Kingdom)

^e KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Adhesion molecules; Diabetes; Insulitis; Linomide; TNF

Indexed keywords

CELL ADHESION MOLECULE; CYTOKINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; ROQUINIMEX; TUMOR NECROSIS FACTOR ALPHA;

AGE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; BLOOD VESSEL; CELL COUNT; CELL FUNCTION; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DIABETES MELLITUS; DRUG EFFECT; DRUG MECHANISM; FEMALE; IMMUNOHISTOCHEMISTRY; INSULITIS; MACROPHAGE; MOUSE; NONHUMAN; OBESITY; PANCREAS ISLET; PHENOTYPE; PRIORITY JOURNAL; PROTECTION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE;

AGING; ANIMALS; B-LYMPHOCYTES; CELL MOVEMENT; CYTOKINES; DENDRITIC CELLS; FEMALE; GENE EXPRESSION REGULATION; HYDROXYQUINOLINES; INSULIN; ISLETS OF LANGERHANS; MACROPHAGES; MICE; MICE, INBRED NOD; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037242660     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(02)00137-6     Document Type: Article

References (65)

1. Makino S., Kunimoto K., Muraoka Y., Mizushima Y., Katagiri K., Tochino Y. Breeding of a nonobese, diabetic strain of mice. Exp. Anim. 29:1980;1-13.
2. Reddy S., Wu D., Swinney C., Elliott R.B. Immunohistochemical analyses of pancreatic macrophages and CD4 and CD8 T cell subsets prior to and following diabetes in the NOD mouse. Pancreas. 11:1995;16-25.
3. Miyazaki A., Hanafusa T., Yamada K., Miyagawa J., Fujino Kurihara H.et al. Predominance of T lymphocytes in pancreatic islets and spleen of pre-diabetic nonobese diabetic [NOD] mice: a longitudinal study. Clin. Exp. Immunol. 60:1985;622-630.
4. Dahlen E., Dawe K., Ohlsson L., Hedlund G. Dendritic cells and macrophages are the first and major producers of TNF-alpha in pancreatic islets in the nonobese diabetic mouse. J. Immunol. 160:1998;3585-3593.
5. Koike T., Itoh Y., Ishii T., Ito I., Takabayashi K.et al. Preventive effect of monoclonal anti-L3T4 antibody on development of diabetes in NOD mice. Diabetes. 36:1987;539-541.
6. Wang Y., Hao L., Gill R.G., Lafferty K.J. Autoimmune diabetes in NOD mouse is L3T4 T-lymphocyte dependent. Diabetes. 36:1987;535-538.
7. Hutchings P.R., Simpson E., O'Reilly L.A., Lund T., Waldmann H., Cooke A. The involvement of Ly2+ T cells in beta cell destruction. J. Autoimmun. 3(Suppl. 1):1990;101-109.
8. Serreze D.V., Chapman H.D., Varnum D.S., Hanson M.S., Reifsnyder P.C.et al. B lymphocytes are essential for the initiation of T cell-mediated autoimmune diabetes: analysis of a new "speed congenic" stock of NOD. Ig mu null mice. J. Exp. Med. 184:1996;2049-2053.
9. Lee K.U., Amano K., Yoon J.W. Evidence for initial involvement of macrophage in development of insulitis in NOD mice. Diabetes. 37:1988;989-991.
10. Yang X.D., Tisch R., Singer S.M., Cao Z.A., Liblau R.S.et al. Effect of tumor necrosis factor alpha on insulin-dependent diabetes mellitus in NOD mice: I. The early development of autoimmunity and the diabetogenic process. J. Exp. Med. 180:1994;995-1004.
11. Jacob C.O., Aiso S., Schreiber R.D., McDevitt H.O. Monoclonal anti-tumor necrosis factor antibody renders nonobese diabetic mice hypersensitive to irradiation and enhances insulitis development. Int. Immunol. 4:1992;611-614.
12. Jacob C.O., Aiso S., Michie S.A., McDevitt H.O., Acha Orbea H. Prevention of diabetes in nonobese diabetic mice by tumor necrosis factor (TNF): similarities between TNF-alpha and interleukin 1. Proc. Natl. Acad. Sci. U. S. A. 87:1990;968-972.
13. Hunger R.E., Carnaud C., Garcia I., Vassalli P., Mueller C. Prevention of autoimmune diabetes mellitus in NOD mice by transgenic expression of soluble tumor necrosis factor receptor p55. Eur. J. Immunol. 27:1997;255-261.
14. Debray Sachs M., Carnaud C., Boitard C., Cohen H., Gresser I.et al. Prevention of diabetes in NOD mice treated with antibody to murine IFN gamma. J. Autoimmun. 4:1991;237-248.
15. Campbell I.L., Kay T.W., Oxbrow L., Harrison L.C. Essential role for interferon-gamma and interleukin-6 in autoimmune insulin-dependent diabetes in NOD/Wehi mice. J. Clin. Invest. 87:1991;739-742.
16. Hultgren B., Huang X., Dybdal N., Stewart T.A. Genetic absence of gamma-interferon delays but does not prevent diabetes in NOD mice. Diabetes. 45:1996;812-817.
17. Wang B., Andre I., Gonzalez A., Katz J.D., Aguet M.et al. Interferon-gamma impacts at multiple points during the progression of autoimmune diabetes. Proc. Natl. Acad. Sci. U. S. A. 94:1997;13844-13849.
18. Rabinovitch A., Sumoski W., Rajotte R.V., Warnock G.L. Cytotoxic effects of cytokines on human pancreatic islet cells in monolayer culture. J. Clin. Endocrinol. Metab. 71:1990;152-156.
19. Baquerizo H., Rabinovitch A. Interferon-gamma sensitizes rat pancreatic islet cells to lysis by cytokines and cytotoxic cells. J. Autoimmun. 3(Suppl. 1):1990;123-130.
20. Delaney C.A., Pavlovic D., Hoorens A., Pipeleers D.G., Eizirik D.L. Cytokines induce deoxyribonucleic acid strand breaks and apoptosis in human pancreatic islet cells. Endocrinology. 138:1997;2610-2614.
21. Ming W.J., Bersani L., Mantovani A. Tumor necrosis factor is chemotactic for monocytes and polymorphonuclear leukocytes. J. Immunol. 138:1987;1469-1474.
22. Belardelli F. Role of interferons and other cytokines in the regulation of the immune response. APMIS. 103:1995;161-179.
23. Pober J.S., Cotran R.S. Cytokines and endothelial cell biology. Physiol. Rev. 70:1990;427-451.
24. Pober J.S., Cotran R.S. The role of endothelial cells in inflammation. Transplantation. 50:1990;537-544.
25. Bevilacqua M.P. Endothelial-leukocyte adhesion molecules. Annu. Rev. Immunol. 11:1993;767-804.
26. Wang B., Kondo S., Shivji G.M., Fujisawa H., Mak T.W., Sauder D.N. Tumour necrosis factor receptor II (p75) signalling is required for the migration of Langerhans' cells. Immunology. 88:1996;284-288.
27. Cumberbatch M., Dearman R.J., Kimber I. Langerhans cells require signals from both tumour necrosis factor-alpha and interleukin-1 beta for migration. Immunology. 92:1997;388-395.
28. Cella M., Sallusto F., Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr. Opin. Immunol. 9:1997;10-16.
29. Yang X.D., Michie S.A., Mebius R.E., Tisch R., Weissman I., McDevitt H.O. The role of cell adhesion molecules in the development of IDDM: implications for pathogenesis and therapy. Diabetes. 45:1996;705-710.
30. Faveeuw C., Gagnerault M.C., Lepault F. Expression of homing and adhesion molecules in infiltrated islets of Langerhans and salivary glands of nonobese diabetic mice. J. Immunol. 152:1994;5969-5978.
31. Martin S., Hibino T., Faust A., Kleemann R., Kolb H. Differential expression of ICAM-1 and LFA-1 versus L-selectin and VCAM-1 in autoimmune insulitis of NOD mice and association with both Th1- and Th2-type infiltrates. J. Autoimmun. 9:1996;637-643.
32. Moriyama H., Yokono K., Amano K., Nagata M., Hasegawa Y.et al. Induction of tolerance in murine autoimmune diabetes by transient blockade of leukocyte function-associated antigen-1/intercellular adhesion molecule-1 pathway. J. Immunol. 157:1996;3737-3743.
33. Hasegawa Y., Yokono K., Taki T., Amano K., Tominaga Y.et al. Prevention of autoimmune insulin-dependent diabetes in nonobese diabetic mice by anti-LFA-1 and anti-ICAM-1 mAb. Int. Immunol. 6:1994;831-838.
34. Herold K.C., Vezys V., Gage A., Montag A.G. Prevention of autoimmune diabetes by treatment with anti-LFA-1 and anti-ICAM-1 monoclonal antibodies. Cell Immunol. 157:1994;489-500.
35. Yang X.D., Karin N., Tisch R., Steinman L., McDevitt H.O. Inhibition of insulitis and prevention of diabetes in nonobese diabetic mice by blocking L-selectin and very late antigen 4 adhesion receptors. Proc. Natl. Acad. Sci. U. S. A. 90:1993;10494-10498.
36. Yang X.D., Michie S.A., Tisch R., Karin N., Steinman L., McDevitt H.O. A predominant role of integrin alpha 4 in the spontaneous development of autoimmune diabetes in nonobese diabetic mice. Proc. Natl. Acad. Sci. U. S. A. 91:1994;12604-12608.
37. Uniyal S., Boeters L., Chakrabarti S., Singh B., Chan B.M. Leukocytes utilize both alpha4 and alpha5 integrins for intraislet infiltration in nonobese diabetic mice. J. Autoimmun. 12:1999;167-176.
38. Hanninen A., Jaakkola I., Jalkanen S. Mucosal addressin is required for the development of diabetes in nonobese diabetic mice. J. Immunol. 160:1998;6018-6025.
39. Tsukamoto K., Yokono K., Amano K., Nagata M., Yagi N.et al. Administration of monoclonal antibodies against vascular cell adhesion molecule-1/very late antigen-4 abrogates predisposing autoimmune diabetes in NOD mice. Cell Immunol. 165:1995;193-201.
40. Gross D.J., Sidi H., Weiss L., Kalland T., Rosenmann E., Slavin S. Prevention of diabetes mellitus in nonobese diabetic mice by Linomide, a novel immunomodulating drug. Diabetologia. 37:1994;1195-1201.
41. Gross D.J., Weiss L., Reibstein I., Hedlund G., Dahlén E.et al. The immunomodulator Linomide: role in treatment and prevention of autoimmune diabetes mellitus. Int. Immunopharmacol. 1:2001;1131-1139.
42. Hedlund G., Link H., Zhu J., Xiao B.G. Effects of Linomide on immune cells and cytokines inhibit autoimmune pathologies of the central and peripheral nervous system. Int. Immunopharmacol. 1:2001;1123-1130.
43. Karussis D.M., Lehmann D., Slavin S., Vourka-Karussis U., Mizrachi-Koll R.et al. Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide. Ann. Neurol. 34:1993;654-660.
44. Diab A., Michael L., Wahren B., Deng G.M., Björk J.et al. Linomide suppresses acute experimental autoimmune encephalomyelitis in Lewis rats by counter-acting the imbalance of pro-inflammatory versus anti-inflammatory cytokines. J. Neuroimmunol. 85:1998;146-154.
45. Zhu J., Diab A., Mustafa M., Levi M., Wahren B.et al. Linomide suppresses chronic-relapsing experimental autoimmune encephalomyelitis in DA rats. J. Neurol. Sci. 160:1998;113-120.
46. Karussis D.M., Lehmann D., Slavin S., Vourka Karussis U., Mizrachi Koll R.et al. Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide). Proc. Natl. Acad. Sci. U. S. A. 90:1993;6400-6404.
47. Bai X.F., Shi F.D., Zhu J., Xiao B.G., Hedlund G., Link H. Linomide-induced suppression of experimental autoimmune neuritis is associated with down-regulated macrophage functions. J. Neuroimmunol. 76:1997;177-184.
48. Karussis D.M., Lehmann D., Brenner T., Wirguin I., Mizrachi Koll R.et al. Immunomodulation of experimental autoimmune myasthenia gravis with linomide. J. Neuroimmunol. 55:1994;187-193.
49. Tarkowski A., Gunnarsson K., Stålhandske T. Effects of LS-2616 administration upon the autoimmune disease of (NZB×NZW) F1 hybrid mice. Immunology. 59:1986;589-594.
50. Tarkowski A., Gunnarsson K., Nilsson L.A., Lindholm L., Stålhandske T. Successful treatment of autoimmunity in MRL/1 mice with LS-2616, a new immunomodulator. Arthritis Rheum. 29:1986;1405-1409.
51. Karussis D.M., Meiner Z., Lehmann D., Gomori J.M., Schwarz A.et al. Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double-blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation. Neurology. 47:1996;341-346.
52. Andersen O., Lycke J., Tollesson P.O., Svenningsson A., Runmarker B.et al. Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis. Neurology. 47:1996;895-900.
53. Coutant R., Landais P., Rosilio M., Johnsen C., Lahlou N.et al. Low dose linomide in Type I juvenile diabetes of recent onset: a randomised placebo-controlled double blind trial. Diabetologia. 41:1998;1040-1046.
54. Vukanovic J., Isaacs J.T. Linomide inhibits angiogenesis, growth, metastasis, and macrophage infiltration within rat prostatic cancers. Cancer Res. 55:1995;1499-1504.
55. Ichikawa T., Lamb J.C., Christensson P.I., Hartley Asp B., Isaacs J.T. The antitumor effects of the quinoline-3-carboxamide linomide on Dunning R-3327 rat prostatic cancers. Cancer Res. 52:1992;3022-3028.
56. Vukanovic J., Hartley Asp B., Isaacs J.T. Inhibition of tumor angiogenesis and the therapeutic ability of linomide against rat prostatic cancers. Prostate. 26:1995;235-246.
57. Gonzalo J.A., Gonzalez Garcia A., Kalland T., Hedlund G., Martinez C., Kroemer G. Linomide, a novel immunomodulator that prevents death in four models of septic shock. Eur. J. Immunol. 23:1993;2372-2374.
58. Gonzalo J.A., Gonzalez Garcia A., Kalland T., Hedlund G., Martinez C., Kroemer G. Linomide inhibits programmed cell death of peripheral T cells in vivo. Eur. J. Immunol. 24:1994;48-52.
59. Harring A.C., Xu Z., Andersson G., Hedlund G. Linomide enhances apoptosis in CD4+ CD8+ thymocytes. Scand. J. Immunol. 46:1997;488-494.
60. Larsson E.L., Joki A., Stålhandske T. Mechanism of action of the new immunomodulator LS2616 on T cell responses. Int. J. Immunopharmacol. 9:1987;425-431.
61. Dahlen E., Andersson M., Dawe K., Tellander A.C., Brunmark C.et al. Inhibition of autoimmune disease by the immunomodulator Linomide correlates with the ability to activate macrophages. Autoimmunity. 32:2000;199-211.
62. Dohlsten M., Sundstedt A., Björklund M., Hedlund G., Kalland T. Superantigen-induced cytokines suppress growth of human colon-carcinoma cells. Int. J. Cancer. 54:1993;482-488.
63. Baron J.L., Reich E.P., Visintin I., Janeway C.A. Jr. The pathogenesis of adoptive murine autoimmune diabetes requires an interaction between alpha 4-integrins and vascular cell adhesion molecule-1. J. Clin. Invest. 93:1994;1700-1708.
64. Gately M.K., Renzetti L.M., Magram J., Stern A.S., Adorini L.et al. The interleukin-12/interleukin-12-receptor system: role in normal and pathologic immune responses. Annu. Rev. Immunol. 16:1998;495-521.
65. Zhu J., Bai X.F., Hedlund G., Björk J., Bhakiet M.et al. Linomide suppresses experimental autoimmune neuritis in Lewis rats by inhibiting myelin antigen-reactive T and B cell responses. Clin. Exp. Immunol. 115:1999;56-63.